Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 1, 2001, Pages 41-47

  Madsen, Hanne ^a   Enggaard, Thomas Peter ^a   Hansen, Lone Lindal ^a   Klitgaard, Niels Anders ^a   Brøsen, Kim ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTOLBUTAMIDE; CARBOXYTOLBUTAMIDE; CYTOCHROME P450 2C9; FLUVOXAMINE; FLUVOXAMINE MALEATE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VOLUNTEER;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CATALYSIS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FLUVOXAMINE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; SEROTONIN UPTAKE INHIBITORS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TOLBUTAMIDE;

EID: 0035133746     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.112689     Document Type: Article

References (36)

1. Effect of cigarette smoking on fiuvoxamine pharmacokinetics in humans
2. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 but also CYP1A2 activity
3. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
4. Differences in interactions of SSRIs
5. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes
6. Inhibitors of imipramine metabolism by human liver microsomes
7. Effect of fiuvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects
8. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
9. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide
10. Fluvoxamine and fiuoxetine: Interaction · studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients
11. Fluvoxamine inhibits the CYP2C19-catalyzed metabolism of proguanil in vitro
12. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine
13. Effect of fluvoxamine on the pharmacokinetics of quinidine
14. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: In vitro studies with tolbutamide and (S)-warfarin using human liver microsomes
15. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin phydroxylation
16. Are pharmacokinetic drug interactions with the SSRIs an issue?
17. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
18. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9
19. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers
20. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
21. Clinical pharmacokinetics of fluvoxamine
22. Interaction of fluvoxamine with warfarin in an elderly woman
23. Quantitative determination of tolbutamide and its metabolites in human plasma and urine by high-performance liquid chromatography and UV detection
24. Tolbutamide hydroxylation in humans: Lack of bimodality in 106 heathy subjects
25. A fluvoxamine-caffeine interaction stud
26. Genetic analysis of the human cytochrome P450 CYP2C9 locus
27. The role of the CYP2C9-Leu 359 allelic variant in the tolbutamide polymorphism
28. Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population
29. Toxic reaction following the combined administration of fluoxetine and phenytoin: Two case reports
30. Fluoxetine inhibition of phenytoin metabolism
31. Antidepressant interactions with warfarin
32. Overview of the pharmacokinetics of fluvoxamine
33. Vitamin C for paroxetine- and fluvoxamineassociated bleeding
34. Fluvoxamine-associated bleeding
35. Fluvoxamine: A review of its safety profile in world-wide studies